With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite

About five years ago, former Teva Pharmaceutical CEO Jeremy Levin launched Ovid Therapeutics with a plan to develop treatments for rare brain diseases.

Now, with the completion of a clinical trial on the horizon anticipated to provide enough data to file for FDA approval, the 55-person biotech has recruited a Novartis (NYSE: NVS) executive to map out its commercialization strategy.